New nuclear imaging studies available for clinical use

Abstract

Several new diagnostic drugs for use in nuclear medicine have become commercially available in the past year. Recently revised Nuclear Regulatory Commission regulations pertaining to nuclear imaging studies are being adopted by the Iowa Department of Public Health. The author reviews clinical uses of the new drugs, and changes in regulations that allow broader use of existing radiopharmaceuticals.